The two stocks form some of their larger holdings and they have said that they are here for the 3+ year time frame.
In that respect they would continue regular coverage of IXC given that they follow this stock fulltime and have the privy to due diligence others do not - that once shared aids in sp appreciation (Look at PAR 2017/2018). So not on a retainer to cover the stock, but it remains in their best interest to do so.
Ann: Initial FDA and EMA Advice on Presendin Development, page-101
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
